Kymab and MD Anderson Announce Strategic Partnership in Immuno-Oncology Research & Development

Cambridge, UK, and Houston, Texas: Kymab, the leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit, today announced a strategic cancer drug discovery and development alliance.

The alliance seeks to discover and develop novel human therapeutic antibodies to treat a variety of cancers. Kymouse™ — Kymab’s human antibody discovery platform — has unparalleled diversity as it yields antibodies with highly attractive drug-like properties, and is able to rapidly identify and enrich rare high-quality molecules that can be explored as novel therapeutics.